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hUl'lIopenlive adminisll"lllion of eht' proleinue inhibitor .pro> 
tinin ClU!ieS reduction in blood 100 and homologoul blood require-
ment In pallmb unde.-goira, eardiac l urgery. Ta ucertain the blood. 
.... ing e:tre<:1 of aprotinin and 10 obtRin funher information about 
the mode of action, 40 patienu undergoing primary myocardial re-
v.ueularizalion wert randomly aasigned 10 r~ive elther .prolinin 
0' placebo Irealment. Aprollnin was ,iven as a bolus of 2 X 10' 
b llikn:in inaclivalor unil, (KIU) befate l urgery followed by 111 con· 
tinuouJ infusion or 5 X 101 KIUfh durlng l urgery. Addition.Ur, 2 
X 10' KIU were added to the pump prime. Strict erileria were uied 
to ob"in a homogeneou5 patient Hleelion. Total blood 10ft W'I re-
duced from 1,431 ± 760 nt! in Ihe eonlrol !T0up 10 738 ± 411 ml In 
Ihe .prolin;n group (P < 0.05) .nd the homologoul blood require-
menl from 838 ± 963 ml 10 16! ± !08 ml (p < 0.05). In the control 
group, 2.3 ± 2.2 U of homolo!joul blood or blood produe15 were 
given, and in the aprolinin group. 0.63 ± 0.96 U were given (P 
< 0.05). Twenty-five perccnt of pllients in the conlrol !'oup and 
63~ in Ihe aprolinin group did not reeeive banked blood or ho-
mologous blood produets. The lIelivllled dOlling lime as an jndielltor 
of inhibition of Ihe eonillet phase of eollgulation was signifieantly 
inerell!led before hepuiniulion In Ihe .protinin group (I4t ± l! . 
w. 122 ± 25 s) and rem.ined .ignifietntly increased untl! heparin 
W" neulrllli~ed after cardiopulmonllry byp:u5 (CPB). The concen-
trlltion oflhe thrombin-antithrombin 111 complelt was significantly 
deereued at the end ofCPB in the aprotinin group, indicating leu 
thrombin generalion in Ihe 'prolinin.lrealed group. The lolal con-
(ent ralion ofthe fibrinogen-fibrin splil produc15 (FSP) and tbe . plil 
produets of the cross-linked fibrin (D-dimer.) were also lignifieantly 
reduced due to allenuatcd prolcolylie act ivilies of thrombin and 
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plumin. The raults of the fibrin plate auay revealed higher !ibri· 
nolytk aetivity during CPB in the eonlrol roup. The raultl dem_ 
oOl trale the bc:neficial elfeet of high-dote . protinin IrCilment on 
blood 1051 and homologou! blood requirement. Thi. eifert ein be 
allribuled to Ihe inhibilion of the conl lel phaH of co.plalion .nd 
the consequendy reduced thrombotie Ind fibrinolytic activity during 
Ind .(Icr CPB. (Key word.: Aneuhe,il: eudiae. Coagulalion, cu. 
diopulmonary bypau: aprolinin. Surgery: cardiae.) 
INTRAOPERATIVE ADM INISTRATION of the proteinase 
inhibitor aprotinin leads to a reduction in blood 1055 in 
cardiac surgery. thus decreasing the necessity for trans-
fusion ofbanked b lood.I~6 The beneficial effect of other 
drugs, including desmopressin acetate (DDAVP. Rorer 
Pharmaceuticals, Ft. Washington. PA),1 prostacyclin,8and 
dipyridamole,9 on blood loss in patienu undergoing car-
diac surgery has already been proven in controlled clinical 
studies. Aprotinin is a naturally occurring enzyme inhib-
itor derived from bovine lungs. It acts on trypsin, plasmin, 
tissue-kallikrein, and to a lesser degree. on plasma-kam-
krein. 10.11 Moreover, it is reported to have direct platelet-
preserving properties in very high dosages. 12 Although 
aprotinin has been weil known for many years and has 
been widely used for many surgical indications,lo its blood 
saving properties have only become evident since it has 
been used in very high doses. 4 The rationale for these 
high dosages is to achieve aprotinin plasma concentrations 
during cardiopulmonary bypass (CPB) that are able to 
inhibit kallikrein activation. 
Based on previous investigations/' we postulated that 
the clinical effecl of aprotinin is based mainly on the in-
hibitio n ofthe eontaet phase of coagulatio n. During CPB, 
this system is aetivated by contaet of blood with artificial 
surfaces of the extraeorporeal circuit. ls This aetivation 
cannot be completely inhibited by heparin. However, the 
postoperative bleeding tendency after cardiac surgery 
seems to be primarily due to impaired platelet funetion.l~ 
Intraoperative stimulation of coagulation with generation 
ofthrombin may lead to plate letactivation. It is therefore 
coneeivable that additional inhibition of the contact phase 
of coagulation by aprotinin might cause a diminution of 
this bleeding tendency during and after CPB. However, 
the mecha nism underlying the benefit from aprotinin has 
not yet been elucidated eompletely. 
This prospe1:tive, do uble-blind, placebo-comrolled 
1119 
study was undertaken for two reasons: I) to aseertain the 
blood-saving elfeet of high-dose aprotinin in a homoge-
neous group of patients undergoing cardiae surgery, and 
2) to obtain further information about the mode of ac tion 
of aprotinin. 
Methods 
Forty patients schedu led for eleetive primary myoear-
dial revascularization gave informed consent to participate 
in this study, which had been approved by the loeal ethical 
eommiltee. The study group eomprised only male patients 
wilh preoperative normal left ventricular function (eje<:-
lion fraction [EF] > 40%i left ventrieular end-diastolic 
pressure [LVEDPj < 20 mmHg) and apreoperative he-
moglobin concentration > 13.5 gldl who were not re-
ceiving preoperative anticoagulant treatment. Antiplatelel 
therapy wasstopped at least 5 days before surgery. Criteria 
for exclusion from the slUdy were any surgical procedures 
other than revascularization, duration of operation 
greater than 360 min, and reexploration due to surgical 
bleeding, which was defined as an evident bleeding source 
found during reexploration. 
Patients were randomly assigned to one of two groups: 
the aprati nin group (group A) and the control group 
(group C). Aprotinin and the respective placebo were 
provided by the manufacturer (Bayer AG, Leverk\lsen, 
FRG) in identical packages, each containing 12 boules 
that eould only be identified by the mndom number. Each 
boule of aprolinin contained 5 X lOs kallikrein inaetivator 
units (KIU) (= 70 mg) aprotinin in 50 ml 0.9% saline 
solution, and the placebo boules eontained only saline. 
The following dosage regimen was appHed: after induc-
tion of anesthesia and before surgery, patients received 
a loading dose of 2 X 10(1 KIU aprotinin over a 15-min 
period followed by a continuous infusion of5 X 105 KIU 
per h administered by an infusion pump for the entire 
duration of surgery. An additional bolus of 2 X 106 KJU 
wasadded to the pump prime ofthe heart- lung maehine. 
Patients in group C received an equal volu me of saline. 
The indic:ation for intra- and postoperative transfusion 
of homologous blood or blood products was defined as a 
hematocrit of less than SO%. T he hematocrit was mea-
sured every 4 h within the fint 24 h postoperatively and 
then every 8 h undl discharge from the lCU. 
Anesthetie, operative, and bypass management were 
standardized. Anesthesia was induced by Runitrazepam 
(0.02 mg/kg) and additional fentanyl (10-20 pg/ kg). 
Pancuronium (0.1 mg/ kg) was used to faei li tate tracheal 
intubation. An arterial catheter via the radial artery and 
a pu lmonary artery catheter via the right internal jugular 
vein were inserted after induction. Anesthesia was main-
tained with additional fentanyl. Ir necessary, enRurane 
or isoflurane was added during sternotomy. 
Mueosa heparin (375 U/kg,Roche, Basel, Switlerland) 
was injected via a central venous catheter before aortic 
eannulation. Further heparin (125 U I kg) was adrninis-
tered if the activated dOlling time (ACT) deereased helow 
400 s. T he ACT was eootrolled every half hour during 
heparinization. The extracorporeal circuit consisted ofa 
bubble oxygenator (HiRex D 700, Dideco, Mirandola, 
Italy) that was primed with a 1,400 ml erystalJoidsolution 
eontaining 5.000 units of additional heparin , a cardiotomy 
reservoir (Dideco 0742, Mirandola, ftaly), roller pumps, 
and polyvinyl tubing without an arterial filter. Cardio-
pulmonary bypass was performed with moderate hypo-
therrnia of 30° C and a Aow rate of 2.4 I · min- I • m- t . 
Myocardial preservation wasaehieved by infusion of I ,000 
ml cold cardioplegic solution (Bretschneider HTK, F. 
Köhler Chemie, Alsbach, FRG, eontaining 9 mM potas-
sium and 180 mM histidine) ioto the aortk root after aortic 
cross-damping. After completion of CPB, residual heparin 
was neutralized with protamine chloride in a ratio of 1.5 
mg per 125 U of the initia l heparin dose. A cell separator 
without a special heparin admin istration suction Hne 
(Haemonetics, Munich, FRC) was only used to eoncen-
trate and wash the remaining blood of the oxygenator 
after termination of the bypass. 
Mechanical ventilation was maintained postoperatively 
umil peripheral rewarming and stable cireulatory condi-
tions were aehieved and no major bleeding was noted. 
The reservoir ofthe heart-Iung maehine was used to col-
leet shed mediastinal blood for retransfusion dur ing the 
early postoperative phase. T he drainage blood was re-
transfused up to 6 h after surgery if at least 250 ml were 
collected and its volume replacement was necessary. 
lntra- and postoperative crystalloid and colloid infusion 
were recorded until the patient's discharge from the in-
tensive care unit (ICU). Blood transfusions needed until 
discharge from the hospital were also reeol'ded. Intra-
operati ve blood loss was assessed by weigh ing the gaUles 
and sponges and measuring the content of the suetion 
reservoir. The Auid used for rinsing was subtracted from 
this amount. The intraoperative bleeding tendency was 
assessed by the surgeon and the anesthesiologist after 
protamine administration using a score ranging from one 
(minimal) 10 foul' (exeessive). POSloperative blood loss via 
the chest LUbes was measured 6, 12, and 24 h postoper-
alively and at the removal of the ehest LUbeS. 
The red blood cell mass of the patients was calcu lated 
preoperatively, on the first postoperative day, and on dis-
charge from the ICU by multiplying hematoerit with the 
blood volume, 15 which was derived from standard curves 
using the sex, age, and weighl orthe patient. 
Blood sampies were taken from the central venous 
catheter 01' the arterial port of the extracorporeal eircu it 
at the followi ng times: I) after induction of anesthesia 
before aprolinin infusion, 2) before heparin administra-
tion, 3) 5 min after the start of CP8, 4) 30 min after the 
start ofCPB, 5) at the end ofCPB, 6) after chest closure, 
7) 2 h postoperative1y, 8) on the first postoperative day, 
and 9) 7 days postoperatively. After discarding the first 
10 ml, blood was drawn into EDTA tubes for platelet 
count, leukocyte count, and hematocrit or into acid-ci-
trate-dextrose (ACD) solution (4:1) for all other mea-
surements. The ACD blood was immediately centrifuged 
at 3,000 g for 10 min at room temperalure, and the 
plasma was separated from the cellular components. All 
plasma sampies were frozen at -40 0 C in aliquots and 
thawed only before testing. 
Tissue plasminogen activator (tPA) concentration, the 
split products of cross-linked fibrin (D-dimers; Boehringer 
Mannheim, FRG), total degradation products of fibrin-
ogen and fibrin (FSP; Organon Teknika, Heidelberg, 
FRG), and the complex of thrombin with antithrombin 
111 (TAT; Behring, Marburg, FRG)16 were determined 
by sandwich ELISA using polydonal and monodonal an-
tibodies. Calibration was performed with standard ma-
terial supplied by the manufacturers. Results are given in 
nanograms per milliliter. Aprotinin plasma concentrations 
were quantified by means of a competitive ELISA ac-
cording to Mue1ler-Esterl et al. 17 Total plasma protein 
was quantified with the Biuret method (Boehringer 
Mannheim, FRG). Spontaneous fibrinolytic activation in 
the native sampies and in their (essentially inhibitor-free) 
euglobulin fraction was estimated on plasminogen con-
taining human fibrin plates. 18 Any development ofa lysis 
zone, regardless ofits area, was considered as an indication 
of extrinsic plasminogen activator(s) in the sampIe. 
To determine the ACT, 2 ml ofblood were collected 
into vacuum tubes containing 12 mg eelite. The Hemo-
ehron 800 (International Technidine Corp., NJ) was used 
according to the instructions ofthe manufacturer. Single 
measurements of ACT were performed every half hour 
and at all intraoperative measurement times. If the ACT 
exceeded 1,200 s, the measurement was stopped. Pro-
thrombin time, thrombin time, and activated partial 
thromboplastin time (aPTT) were measured by routinely 
applied clotting methods. Bleeding time was determined 
after induction of anesthesia, after neutralizing the hep-
arin effect with protamine chloride, and 4 h postopera-
tively in the ICU. Since the ear lobe is the only part of 
the body within (he reach of the anesthesiologist during 
surgery, sampies were taken from this body part. The 
subaqual bleeding method that isa modified Duke method 
was applied. 19 
Summary data of all variables are, if not otherwise 
stated, expressed as mean ± SD. Analysis of variance 
(ANOVA) was used ifappropriate. The Mann-Whitney 
U test was applied where data did not follow anormal 
distribution according to the results of Shapiro's test for 
normality. The chi-squared test was used for categorical 
data. P < 0.05 was considered statistically significant. 
Results 
Data of20 patients in group C and 19 patients in group 
A were evaluated. One patient (group A, patient 4) was 
excluded from analysis because of an additional intra-
operative procedure (resection of a left ventricular aneu-
rysm) that led to a prolongation of the operation. Reex-
ploration due to surgical bleeding was not necessary. 
As shown in table I, patients in the lwo groups were 
comparable in terms of age, weight, operation, :md CPB 
time. Thirteen patients in group C and II patients in 
group A also had additional internal mammary artery im-
plantation. 
Intraoperative blood loss per patient was 636 ± 322 
ml in group C and 363 ± 159 ml in group A (P < 0.05). 
The postoperative blood loss is given in figure I. The 
mean cumulated loss 6,12, and 24 h postoperatively per 
patient was 721 ± 471 ml, 894 ± 491 ml, and 1,169 
± 605 ml, respectively, in group C and 303 ± 209 ml, 
399 ± 251 ml, and 584 ± 295 ml, respectively, in group 
A. The total postoperative blood loss per patient until 
removal ofthe chest tubes was 1,431 ± 760 ml in group 
C and 738 ± 411 ml in group A (P < 0.05). One patient 
(patient 37) in group C had a total blood loss of 3,550 
ml. Since all hemostatic parameters were within the nor-
mal range, this blood loss was probably due to surgical 
bleeding; however, reexploration was not performed in 
this patient. Even after excluding this patient from anal-
ysis, the difference in blood loss between the groups was 
still significant (P < 0.05) at each stage. A total of 663 
± 171 ml per patient (group C) and 731 ± 283 ml per 
patient (group A) autologous packed cells gained with the 
cell separator from the oxygenator were retransfused (not 
significant [NS]). Two patients in group C and one patient 
in group A received homologous blood intraoperatively. 
A mean of 431 ± 367 ml of drainage blood (maximum, 
1670 ml [patient 37])and 147 ± 188 ml ofdrainage blood 
(maximum, 810 ml [patient 39]) was retransfused via the 
reservoir postoperatively in group C and A, respectively. 
The mean amount ofintra- and postoperatively transfused 
whole blood was 838 ± 963 ml per patient in group 
C and 163 ± 308 ml per patient in group A (P < 0.05). 
A total of 2.3 ± 2.2 U per patient of homologous blood 
or blood products (i.e., blood, packed cells, or fresh-frozen 
plasma) were given in group C and 0.63 ± 0.96 U per 
patient in group A (P < 0.05). In group C, 46 U of ho-
mologous blood were transfused to 15 patients, repre-
senting a mean of 3.1 U per patient; whereas in group A, 
12 U were given to seven patients, representing a mean 
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" Mean ±SD 55 ± 8 ?6 ± 10 230 ± 68 72 + 31 
IMA - internal mammary graft. 
of 1.7 U per patient. Twenty-five percent of the patients 
in group C and 63% in group A were discharged without 
receiving any banked blood or homologous blood prod-
UClS. 
Intraoperative blood loss correlated significantly with 







,- ,. ~ 1500 , : . . 




.... .... .... .... 
FIG. I. Box plot of intl1l- and postopel1ltive bloOO 1055. The top of 
the box repreKnLS the ?5th percentile, the line in the middle the me-
dian. the bauom the 25th percentile, and the notches the 95% oonli-
dencc baumb. The top and the boctom ofthc whi,kers are awlCiatcd 
with the 90th and 10th perccntilc, rcspectivcJy, and thccircles rcprcsent 
values above and below these perccntiles. Thc postoperative data are 
cumulalive vaJues. Thc loplTK)$( circ1e in the control group rcprcsents 
a patient(patient 37). who had a total pos;topcntive bloOO I055of3,550 
ml. Ewen after remov;ng this patient from anal)";s, however, the dif_ 
ference bctween thc groupli still remaincd significant. 
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58 ± 10 79 ± 9 234 ± 45 88 ± 27 
There were no lignilicant difrerences of the variables between the 
groups. 
A (fig. 2). The correlation belween total blood require-
ment and duration of operation was also only significanl 
(P < 0.05) in group C. 
The bleeding score as an assessment of intraopetative 
bleedi'ng tendency(ranging from minimal [1] to excessive 
[mQ 
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FIG. 2. Corrclation betwccn intraopcl1ltive blood lass and duratioo 
of opcratioo. The intraoperative blood lau was a.ssesscd by weighing 
the gauzes and sponges and mcasuring the content ofthe suction res-
ervoir. 81000 10ß and time of operation correlatcd significantly in the 
comrol group but did not correlate in the aprotinin group. 
(4]) was 3.15 in group C and 2.3 in group A (P < 0_05). 
The hematocrit on the first postoperative day was 33.7 
± 4.1% in group e and 37.9 ± 2.9% in group A (P 
< 0.05). The preoperatively ealculated red blood cell mass 
was 2,428 ± 283 ml and 2,572 ± 300 ml in groups C and 
A, respectively (NS). At discharge from the ICU. it dif-
fered significantly: 1,846 ± 234 ml in group C and 2,027 
± 168 ml in group A (P < 0.05). This differenee remained 
signifieant until the seventh postoperative day when the 
red blood cell mass was 1,954 ± 312 ml in group e and 
2,137 ± 214 ml in group A (P < 0.05). The elapsed time 
between end of ePB and ehest dosure was 55 ± 19 min 
in group e and 46 ± 11 min in group A (NS). After CPB, 
the preoperative platelet count dropped from 213 ± 58 
X 109/ltoI29±58X 109/1 in groupCand from 193 
± 44 X 109/ 1 to 115 ± 47 X 109/ 1 in group A (NS). 
The ACT, whieh was in a comparable range preop-
eratively in the two groups. was significantly increased 5 
min before administration of heparin in group A (141 
± 13 s VS. 122 ± 25 5) and remained significantly higher 
until antagonizing the effect of heparin after CPB. The 
aPTT was also significantly increased before heparin in 
group A (34 ± 2.8 svs. 74 ± 7.3 s; P < 0.05)and remained 
significamly prolonged until 2 h after surgery (66 ± 23 s 
us. 45 ± 25 s). The preoperative bleeding time in groups 
C (180 ± 45 s) and A (178 ± 27 s) were within the normal 
range; however, 4 h postoperatively, it was 213 ± 46 s in 
group A and 290 ± 114 s in group C (P < 0.05). 
There were no differenees in the total plasma protein 
eoneentrations between the groups throughout the study 
period. The coneentration of the TAT complex is given 
in figure 3. The differences between the groups 30 min 
after start ofCPB and at the end ofCPB were significam 
(P< 0.05) with 48 ± 21 ng/ml and 82 ± 42 ng/ ml in 
group C compared to 24 ± 11 ng/ml and 42 ± 14 ng/ 
ml in group A. 
, .. '" 
" • conlrol 
• I 70 oaprollnln • 
60 • •• • • 
• I ~ ., • • • • • • , • 
" • • 8 • 
" 
• ! 8 : I !i 
• I • 2<J , • 




• < 0.65 vs ODfll.a 0 
5 mln aller 30mln a"er CPBend end 01 
CPB Slart CPB Slart operallon 
Fm. 3. Course oflhe Ihrombin-amilhrombin 111 complex (TAT) 
during eXlracorporeal circulation 3nd at the end of operation. Each 
dot or drele represenl5 a single value. whereas Ihe lines connect Ihe 
mean ± so values. 
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FIG. 4. Concentration oflhe SpUl produCIS of cross-linked fibrin (0-
dirnen). All valua are mean ± SO. OuringCPB, there wasasignificanlly 
increased generation of D-dirners in Ihe control group a5 compared 
10 Ihe aprOlinin group. indicating less fibrin formation and len fibri· 
nolYlic aClivily in thc aprotinin-rreated patients. 
The concentration of the split products of the cross-
linked fibrin (D-dimers) increased in both groups during 
surgery (fig. 4). The inerease was less in the aprotinin 
group, however, and was 532 ± 1,425 ng/ml and 497 
± 1,398 ng/ml 30 min after onset ofCPB and at the end 
of CPB, respectively, which is significantly less than the 
values of group C (2,155 ± 2,300 ng/ml and 3,131 
± 2,755 ng/ml). The FSP concentrations showed a similar 
course (fig. 5). At the end ofCPB. the coneentration was 
10,824 ± 7,261 ng/ml in group C and 2,510 ± 3,932 
ng/ml in the group A (P < 0.05). 
The fibrin plates revealed increased fibrinolytic aetivity ' 
during the entire course of ePB in the control group 
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FIG. 5. TOIllI degradalion producl5 offibrinogen and fibrin. Values 
shown in the graph are rnean ± SO. Ouring Ihe whole period ofCPB, 
Ihere was a s.ignificam increase in ehe control group 8$ compared to 
the aprotinin group. However, cornpari50n ofthe preoperalive value 
and the concentration at Ihe end of CPB reveals a signilicanl increase 
in the aprotinin gToup 35 weil. 
TABU: 2 FibrillOlytie Aetivity on Fibrin Plates 
TI_ "'<f'>"'I;"" 
Prior to oper.'IIion Euglobulin 
Native 
Prior to hcpilrin Euglobulin 
Native 
5 min ~fler start ofCPB Euglobulin 
Native 




Thc values rcprcsc:nt thc Olm orthe lysis spotS on the fibrin plates. 
The area il proportionale 10 the fibrinolytic activity in the plOlJma. 
The euglobulin row reprcsc:nl5the va luC! arter rcmoval ofthe inhibitors 
(table 2). In the native sampies, fibrinolytic activity was 
evident in 12 patients 5 min after onsel of ePB and in 
1 S patients 30 min after onsel ofePB in the control grOUpj 
however. this could not be demonstrated 5 min after the 
start of CPB and in eight patients 30 min after the slart 
ofCPB in the aprotinin group (P < 0.05). At the end of 
CPB, however, fibrinolytic activity could be seen in 15 
patien15 in group e and in 14 patien15 in group A. The 
quantitative measuremenl of the lysis spots is given in 
table 2. At the end ofthe operation, no differences cou ld 
be determined. In contrasI, lhe tPA concentration was 
not significantly different during the course of surgery. 
It increased from 6 ± 3.7 ng/ ml preoperatively to 18 
± 10 ng/ ml at the end of CPB in group e and from 6 
± 2.3 ng/ ml to 16 ± 9 ng/ ml in group A. None of the 
laboratory results showed any significant difference arter 
the first postoperative day. 
The aprotinin plasma concentration (fig. 6) dem on-
strated an increase from 152 ± 61 KIU/ ml before heparin 
tO 335 ± 106 KlU/ ml5 min after onset ofePB. There-
after. a continuous decrease was found until the end of 
CPB (191 ± 62 KIU/ ml). Two hours after surgery, the 
aprotinin concentration was 74 ± 31 KIU/ml. 
The postoperative course of all patien15 was uneventful. 
No clinically relevant side effects could be attributed to 
aprotinin treatment. 
Discussion 
This study clearly demonstrates the influence of high-
dose aprotinin treatment given during the entire course 
of open heart surgery on intra- and postoperative blood 
loss. Comparing homogeneous patient groups, a highly 
significant reduction of intra- and postoperative blood loss 
was found in the aprotinin-treated group. This reduction 
led to a concomitant saving of homologous blood. Post-
ControI & ..... p AptOIlfMG ..... p (",,,,'I (m ... '1 , 
29:1: 11 23:1: 11 NS 
0 0 
36 :1:20 17 ± 15 <0.05 
0 0 
48 ± 20 15:1: 15 <0.05 
••• 0 <0.05 72 ± 25 41 ± 28 <0.05 
25 ± 21 , .. <0.05 
77±!I!I 68:1: 50 NS 
!I!I +27 H6 <0.05 
or librioolysis by the euglobulin preparation. All values are given aJ 
mean:t SD. 
operative blood loss was reduced by 48%. whereas the 
banked blood requirement was diminished by nearly 80%. 
The reduced bleeding tendency was clinically evident as 
shown by the different bleeding scores given for the two 
groups by the surgeon and the anesthesiologist. This study 
corroborates the results of ou r previous investigation~ and 
those of others2•4 that also show a numerical discrepancy 
between the degrees of postoperative bleeding reduction 
and transfusion requirement. This discrepaney may be 
explained by the fact that, due to intraoperativeJy de-
ereased blood loss, the red blood eell mass or hematocrit 
remains higher as an effect of aprotinin treatment. thus 
lessening the need for homologous blood transfusion. 
Furthennore, the hemoglobin COOleOl and. consequeOlly. 
hemoglobin loss via ehest tubes are diminished in this pa-
tient group, where the drainage Auid consists mainly of 
infiammatoryexudation.4 
The differences between the two groups with regard 
to bleeding and banked blood requirement agree with 
~ IKIOhnII 
~ :: 
• 350 ~ 300 
~ 250 
~ 200 I 
! :::l-=~c-~I~~. ~'~C~P~'~I1111~~~~-=::::;Jco ~ so 
priorto 5 min eller 30 min aller CPB end end 01 2 hours 
l\(lparin CPB $IM CPB $tatt operation postop 
fiG. 6. Aprotinin plasma concentration. The peak value 5 min afte r 
(he onset ofCPB rcprcsc:nu the bolus of 2 X 10' KIU aprotinin given 
to the pump prime. Despite the continuoul inrusion of 5 X 10) KJ U 
aprotin in per h the concentration decreased towards the end or CPB 
and towards the end of operntion. Values are given al mean ± SO. 
the reSullS of other studies using the same or a similar 
aprotinin dosage regimen. All studies using aprotinin 
during coronary artery bypass grafting showed nearly 
idemical reductions in blood lo~: Bidstrup er 01.,16%2; 
Van Oeveren tl 01., 47%20; and Fraedrich t/ 01 .• 46%'. 
However, the reduction in a group of patients with mis-
cel1aneous types of operations was 29%,& The blood·saving 
effcct in these studies varied between 43'and 88%.4 This 
blood·saving elftet is due not only to reduction of post-
operative blood 1055 but also to diminished intraoperative 
bleeding tendency as shown in the current study. 
The strong correlation between the duration of CPB 
and intraoperative blood loss, which was evident in the 
patients of the control group, (Quld not be demonstrated 
in the aprotinin-treated patients. 
Nevertheless, the mode of action of aprotinin is not 
yet completely dear. Capillary bleeding and oozing in 
cardiac surgery are believed to be due (0 impaired platelet 
function. The most importamconsequence ofCPB isthe 
loss of platelet aggregability. 1' ,21 Platelet activation occurs 
as a direct result of the contact of blood with a symhetic 
surface during CPB. The inHuence ofaprotinin on platelet 
adhesive receptorscould be demonstrated in one study.20 
ConsequeOlly, a direct platelet-preserving property of 
aprotinin has been poslUlated.20 
The effect of aprotinin on platelets-of primary or 
secondary nature-is unquestionable. In accordance with 
others,2 we observed a shorter postoperative bleeding time 
with aprolinin trcatmeOl as a result of better preserved 
platelet function; however, the platelet count did not dif-
fer between bOLh groups during the whole operation. 
The surface-mediated activation ofthe contact system 
of coagulation involves the imeraction of factor XII 
(Hageman factor) and kallikrein (besides high molecular 
weight kininogen and factor XI).t2 Aprotinin may inhibit 
kallikrein. Without the amplifying eifect of kallikrein on 
the conversion of factor XII to Xlla, the contact phase 
activation i5 inhibited or takes place only slowly. Major 
consequences of the surface-mediated activation are the 
stimulation ofboth the intrinsic pathway of coagulationU 
with the effecl ofthrombin formation and the propagation 
of the fibrinol)'tic pathway leading LO pla5minogen acti-
valion. While activation of the contact system has no major 
direct etrect on platelet activation,24 thrombin is a pow-
erful platelet activator, Therefore, it is conceivable that 
the effect of aprotinin on platelets is seconda ry tO the 
inhibition ofthe contact system of coagulation . 
Indeed, the significant reduction of the D-dimers and 
the thrombin-anti thrombin 111 complex concentration 
found in the current study indicates less thrombin gen-
eration, and the results achieved with the fibrin plates 
demonstrate less fibrinolytic activity during aprotinin ap-
plication. The inhibition of the contact phase of coagu-
lation due to aprotinin is responsible for this reduced 
thrombin formation. Both diminished thrombin genera-
lion and fibrinolysiscaused less formation ofthe fragments 
of fibrinogen and fibrin. 
Aprotinin is a powerful plasmin inhibitor.2~ While we 
observed differences in the results ofthe fibrin plates be-
tween the groups, we could not detC1:t any significant dif-
ference in the course of tPA concentration, The immu-
noassay, however. ma)' not differentiate free and com-
plexed tPA. Plasma kallikrein inhibition not only leads LO 
reduced contact activation of coagulation but can also 
cause reduced fibrinolytic activalion,24,26 The current 
findings indicate that endothelial activation of fibrinolysis 
is not inhibited by aprotinin, whereas the activation via 
plasma kallikrein is auenuated. The course of the ACT, 
which is an indicator of contact activation,27 and the 
aPTT elevation with aprotinin treatment refer to the 
inhibition of the contact phase of coagulation. These re-
sults strongly suggest that the inhibition of the contact 
phase of coagulation is the primary effect of aprotin in 
action and therefore responsible for the blood-saving cf-
fect of this drug. This !inding i5 in contrast to the inter-
pretation given by yan Oeveren tt 01,2(1 who focused on 
the direct platelet protective effect of aprotinin on the 
speci fic platclel receptors, Inhibition of fibrinolysis and 
the better preserved ptatelet function are of secondary 
nature. 
The rationale for choosing the given aprotinin dose 
regimen was to get a constant aprotinin plasma concen-
tration of more than 200 KIU/ ml. which is supposed to 
be the threshold of plasma kallikrein inhibition,28 The 
time course of plasma aprotinin concentration revealed 
that the aprolinin dose used did nOI maintain a stable 
concentration throughout CPB. However, the inhibitor 
concentration exceeded 200 KIU/ ml afteronset ofCPB. 
It might be possible that a higher aprotinin concentration 
at the start of CPB is desirable because surface activation 
takes place mainly during the initial phase of CPB. The 
course of the fibrin-fibrinogen split products and the re-
sults of the fibrin plates demonstraled that aprotinin, at 
least in the dosage given, was not able to completely sup-
press the ongoing hem05tatic activation, All parameters 
5howed an increase toward the end of CPB. Further in-
vestigation is needed to ascertain whether this tendency 
can be prevented with another (i.t, , highcr) dose regi men 
ofaprotinin du ring CPB, The interindividual differences 
in the aprotinin levels do seem to warrant the application 
of a body weight-oriented dosage ofaprotinin instead of 
a fixed dose. 
We conclude that high-dose aprotinin treatment has a 
highly beneficial effect on the hemostatic mechanism dur-
ing and after CPB, leading tO a substantial reduction of 
intra- and postoperative bleeding tendency. The most 
likely mechanism of aprotinin action is the inhibition of 
kallikrein. The current results show that the dosage of 
aprotinin does not provide a constant aprotinin concen-
tration during CPB. Further studies are required to de-
lineate the precise mode of aprotinin action and to de-
termine the most effective aprotinin dosage. 
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